GPT Healthcare Q4 FY26: Growth, Higher ARPOB, and the Near-Term Drag from Raipur

GPT Healthcare closed Q4 FY26 with strong top-line momentum and steady profitability, even as its newest hospital weighed on consolidated margins. Revenue rose to ₹128.0 crore in Q4 FY26, up 24.30 percent year on year, supported by improved clinical mix and pricing. EBITDA increased 12.27 percent year on year to ₹25.0 crore, while PAT rose 13.00 percent to ₹14.7 crore. ARPOB, a key pricing and acuity indicator for hospitals, reached ₹40,517 in the quarter.

For the full year, the picture was more mixed. FY26 revenue grew 15.14 percent to ₹478.5 crore, reflecting demand strength across the mature hospital base and the addition of Raipur for part of the year. But consolidated profitability declined as ramp-up losses, higher depreciation, and higher finance costs from the Raipur capex pulled down earnings. FY26 EBITDA came in at ₹90.1 crore, down 1.86 percent year on year, and PAT fell 15.43 percent to ₹42.2 crore. The reported EBITDA margin fell to 18.84 percent in FY26 from 22.10 percent in FY25.

This split between operating strength in the established network and the early-stage drag from a new unit is the defining theme for FY26. Management is positioning the year as a transition year: solid fundamentals in mature hospitals, clinical capability upgrades across the portfolio, and a new growth engine in Raipur that is still in its investment phase.

FY26 in one sentence: better pricing, softer margins

Two metrics explain much of GPT Healthcare’s FY26 story. The first is ARPOB, which rose to ₹39,243 in FY26 from ₹37,180 in FY25. The company attributes this improvement to a stronger clinical mix and ongoing operating efficiencies. The second is occupancy, which fell at the network level as Raipur added beds but was still in early ramp-up.

Overall network occupancy stood at 45.87 percent in FY26. But excluding Raipur, occupancy was 55.90 percent, which management describes as healthy for the mature base. Raipur’s FY26 occupancy was 12.35 percent, and improved to 14.26 percent in Q4 FY26. This is an important detail because the company’s consolidated numbers now include a meaningful capacity base that is not yet fully productive.

The same pattern shows up in EBITDA. Management disclosed that Raipur’s FY26 EBITDA was minus ₹13.8 crore, while mature hospitals delivered ₹103.9 crore. Net EBITDA therefore was ₹90.1 crore. Excluding Raipur, the EBITDA margin would have been 23.06 percent, compared with the reported FY26 EBITDA margin of 18.84 percent.

The earnings impact is not limited to operating losses. Depreciation and finance costs increased by ₹12.8 crore, linked to the Raipur capex. As a result, FY26 profit before tax declined to ₹54.8 crore from ₹69.3 crore in FY25, even though revenue expanded.

Hospital performance: mature base holds, Dum Dum turns, Raipur builds

GPT Healthcare operates five neighborhood tertiary-care hospitals in Eastern India. Four are considered mature: Salt Lake, Agartala, Dum Dum, and Howrah. The fifth is the new Raipur hospital, which commenced operations in May 2025.

Among mature assets, clinical and operational execution remained visible in the hospital-level metrics.

Salt Lake, an 85-bed tertiary surgical hospital, reported FY26 occupancy of 62 percent, up from 58 percent in FY25. ARPOB increased to ₹41,227 in FY26 and was ₹43,862 in Q4 FY26. The hospital is positioned around higher-acuity surgical care, including robotic gastro and bariatric surgeries.

Agartala, the largest facility with 205 beds, reported FY26 occupancy of 52 percent, up from 46 percent in FY25. FY26 ARPOB rose to ₹36,029, with Q4 FY26 ARPOB at ₹37,181. The company highlights its oncology capabilities including LINAC technology, and notes its medical value travel potential.

Dum Dum, a 155-bed tertiary facility, is central to the year’s operational improvement narrative. Management states that ILS Dum Dum returned to profitability with restructuring and describes this as a key turnaround. FY26 occupancy was 66 percent and improved to 71 percent in Q4 FY26. ARPOB increased to ₹42,684 in FY26 and ₹43,483 in Q4 FY26. The commissioning of cardiothoracic and vascular surgery is expected to strengthen its clinical offering.

Howrah, a 116-bed multi-specialty tertiary care hospital, saw FY26 occupancy of 44 percent and Q4 FY26 occupancy of 47 percent. FY26 ARPOB improved to ₹35,767, and Q4 FY26 ARPOB reached ₹37,898. The company points to robotic knee replacement surgeries as a capability that can improve ARPOB and reduce ALOS.

Raipur, the newest 158-bed quaternary care facility, remains a work in progress. Its FY26 occupancy was 12 percent and Q4 FY26 occupancy was 14 percent, but ARPOB is already at the higher end of the network at ₹42,440 for FY26 and ₹44,659 in Q4 FY26. The hospital has commenced renal transplants, has chemotherapy and oncology surgeries operational, and received a license for liver transplant services.

The table shows why management continues to separate the story into two parts. The mature hospitals deliver mid-40s to high-60s occupancy, while Raipur is still in the low teens. Yet Raipur’s ARPOB suggests the capability mix is being built with higher acuity in mind, which aligns with the hospital’s advanced infrastructure and transplant focus.

Operating model and what the numbers imply

GPT Healthcare’s investor presentation describes a proximity-based model: neighborhood tertiary-care hospitals located within densely populated residential areas. This model is intended to create steady footfalls, high accessibility, and trust-led repeat usage. In FY26, management credits mature hospitals for resilient performance supported by steady footfalls and community trust.

The operational metrics suggest the company is steadily improving the quality of revenue. FY26 ARPOB increased to ₹39,243 and average length of stay declined slightly to 3.50 days from 3.54 days in FY25. This combination can be important in hospital economics. Higher ARPOB points to better clinical mix and pricing, while stable or declining ALOS can indicate improved throughput and process efficiency, provided outcomes and quality remain strong.

Volume growth was also visible. FY26 inpatient volumes were 34,401 versus 30,783 in FY25, while outpatient volumes rose to 1,83,557 from 1,59,894. Inpatient revenue increased to ₹398 crore from ₹340 crore, and outpatient revenue increased to ₹74 crore from ₹65 crore.

At the same time, cost pressures were visible in the profit and loss statement. In Q4 FY26, other expenses rose 34.39 percent year on year to ₹57.4 crore, and employee benefit expenses rose 23.03 percent to ₹22.2 crore. For FY26, other expenses rose 24.59 percent to ₹214.2 crore and employee costs rose 15.54 percent to ₹84.4 crore. These increases are consistent with a year in which a new hospital is scaling up staff, services, and marketing, while also absorbing fixed operating costs ahead of occupancy.

The balance sheet reflects this investment phase. Property, plant and equipment rose to ₹265.4 crore in FY26 from ₹202.6 crore in FY25. Lease liabilities increased sharply to ₹69.5 crore from ₹17.2 crore. Despite the expansion, net debt to equity remained negative at -0.12, which management frames as a net-debt-free profile.

Cash generation stayed healthy. Net cash from operating activities rose to ₹81.1 crore in FY26 from ₹67.4 crore in FY25. Investing cash outflow increased to ₹47.2 crore from ₹32.6 crore, consistent with the capex cycle.

Strategy: clinical capability, disciplined expansion, and a clear near-term agenda

Management’s forward path is anchored around occupancy ramp-up, clinical breadth, and capital-efficient growth. The company sets an operational target of at least 70 percent occupancy across mature hospitals over time through disciplined capacity utilization, equipment optimization, and phased expansion.

The short-term roadmap contains specific milestones. The company has signed an MoU for a 150-bed tertiary care hospital in Jamshedpur with an investment of ₹75 crore, targeted for commissioning by end FY27. This project would take total beds to 869, from 719 in FY26. The company also signals planned entry into Tier II cities such as Uttar Pradesh, Assam, and Odisha, and select Tier I locations in Eastern India.

A key element in this plan is capital efficiency. The company states that land and building are funded by developers, while operations are run on fixed rental arrangements. This approach is intended to support faster scaling and quicker ROCE accretion.

Clinical capability expansion is another recurring theme, both for competitiveness and for ARPOB improvement. Agartala launched comprehensive cancer care with PET scan and Linear Accelerator, positioning it as the only integrated oncology unit in Tripura. Howrah commenced robotic knee replacement surgeries, which the company expects to increase ARPOB and reduce ALOS. Dum Dum commissioned cardiothoracic and vascular surgery, and Raipur expanded transplant and oncology capabilities while receiving a liver transplant license.

The company also emphasizes technology as an enabler of efficiency and patient experience. It highlights SPARSH, a home healthcare service for senior citizens, the ILS-My Health app for appointment booking and medical records, and HMIS for electronic medical record management. It also notes that robotic surgical technology at Salt Lake and Howrah has supported more than 750 robot-assisted surgeries from the robot in Salt Lake.

From an investor perspective, the immediate questions are about execution speed and operating leverage. If Raipur occupancy continues to move from low teens toward more sustainable levels, the consolidated EBITDA margin could begin to converge toward the mature-hospital margin profile over time. The presentation implicitly frames FY26 as the trough year for consolidated margins, but that will ultimately depend on ramp-up pace and cost control.

Takeaways for investors

GPT Healthcare’s FY26 results show a business that is still growing in its core and investing for its next leg. Revenue expanded at a healthy pace in both Q4 and the full year, and ARPOB rose as case mix improved. The mature hospital network continued to deliver solid occupancy and profitability, with Dum Dum returning to profitability after restructuring.

The pressure point is clear and largely intentional: Raipur. Low occupancy, start-up operating costs, and higher depreciation and finance costs reduced consolidated margins and PAT in FY26. Management is responding with a focus on ramping occupancy, building advanced clinical programs, and continuing capital-efficient expansion through developer-funded real estate and fixed rentals.

The quarterly theme that emerges is disciplined execution through an expansion year. If the company can lift occupancy in Raipur and push mature hospitals toward the stated 70 percent target, the operating leverage in the model becomes more visible. For now, the numbers suggest a stable base business absorbing a near-term drag to build a larger platform across Eastern India.